Incidence and Management of Elevated Intraocular Pressure with Antivascular Endothelial Growth Factor Agents

Abstract

Purpose: To review recent literature regarding ocular hypertension following intravitreal antivascular endothelial growth factors (anti-VEGF). Method: An electronic literature search was performed using MEDLINE, OVID, and PubMed. Key search terms were elevated IOP, anti-VEGF, sustained IOP elevation in anti-VEGF, chronic intraocular pressure elevation in anti-VEGF, high IOP with anti-VEGF, acute elevation in intraocular pressure with anti-VEGF, glaucoma and anti-VEGF. Result: Transient elevation of intraocular pressure after intravitreal anti-VEGF injection is due to temporary increase in volume, and the acute spike generally does not affect a healthy eye. Caution should be taken in a glaucomatous eye, and pretreatment with an IOP-lowering medication is recommended. Persistent elevation of intraocular pressure is more common than previously thought and may be correlated to several factors including increased number of intravitreal injections. Conclusion: Persistent ocular hypertension may be associated with intravitreal anti-VEGF injections. Physicians should be aware of this condition and monitor their patients for persistent ocular hypertension, especially in eyes with preexisting glaucoma. Prompt diagnosis and treatment can prevent potential loss of vision.

• Anti-vascular endothelial growth factor
• bevacizumab (Avastin)
• glaucoma
• intraocular pressure
• intravitreal ranibizumab (Lucentis)